Overview
PDS Biotech’s oncology pipeline leverages the Versamune® platform and Versamune® plus PDS01ADC in combination with proprietary tumor-specific proteins or peptides (antigens) in the development of targeted cancer immunotherapies.
PDS Biotech’s oncology pipeline leverages the Versamune® platform and Versamune® plus PDS01ADC in combination with proprietary tumor-specific proteins or peptides (antigens) in the development of targeted cancer immunotherapies.
This website use cookies to facilitate the use of the website, improve its performance and security, personalize the proposed content.